Tiziana Life Sciences (TLSA) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tiziana Life Sciences has secured funding from the ALS Association to conduct a 20-patient clinical trial for its innovative intranasal foralumab, a potential therapy aimed at treating ALS. This trial will explore the drug’s safety and early-stage efficacy, with hopes of slowing disease progression in ALS patients. The company’s unique approach aligns with the ALS Association’s mission to find new treatments for this devastating disease.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Here’s Why Jefferies Says “Sell” Palantir (PLTR) Stock
- Shareholder Alert for Xiao-I Corp. (NASDAQ:AIXI)
- Comcast Stock Rises on $7B NBCUniversal Cable Channels Spinoff Plans
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
